Allogeneic cortical lamina with apical buccal access for combined osseous & mucogingival defects around multiple adjacent teeth

Arrow Development S.L.0 个研究点目标入组 15 人开始时间: 2023年11月28日最近更新: 2024年3月18日

试验速览

暂无简介。

•1. Informed consent after detailed information
•2. Adults at least 18 years of age
•3. Patients with multiple recessions (=2 teeth) type III with shallow vestibule depth and keratinized gingiva that do not include molars, and may be in the upper and lower jaw.
•4. Patients who, in the three-dimensional x-ray, present a vestibular cortex less than 1mm thick
•5. Healthy or periodontally treated patients
•6. Systemically healthy or with completely controlled or stabilized diseases. A medical report will be requested that confirms the stabilization of the specific disease.
•7. General plaque control (FMPS) = 25% (O'Leary et al 1972)

•1. Pregnant or breastfeeding patients
•2. Uncontrolled medical conditions
•3. Uncontrolled periodontal disease
•4. Patients treated with any medication that affects gingival conditions such as causing hyperplasia
•5. Alcohol and/or drug abuse
•6. Do not sign informed consent
•7. Despite having root recessions, it presents a cortex greater than 1mm in the 3D CBCT and therefore another type of technique is considered necessary.

发起方

Arrow Development S.L.